ABCC1 | ATP-binding cassette, sub-family C (CFTR/MRP), member 1 | Cancer-related genes FDA approved drug targets Plasma proteins Predicted membrane proteins Transporters
| | | | | Expressed in all |
ANO1 | Anoctamin 1, calcium activated chloride channel | FDA approved drug targets Plasma proteins Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
CA4 | Carbonic anhydrase IV | Disease related genes Enzymes FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CD2 | CD2 molecule | CD markers FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CD4 | CD4 molecule | CD markers FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | | | | Expressed in all |
CD44 | CD44 molecule (Indian blood group) | Blood group antigen proteins Cancer-related genes CD markers FDA approved drug targets Plasma proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Expressed in all |
CPT1A | Carnitine palmitoyltransferase 1A (liver) | Disease related genes Enzymes FDA approved drug targets Mitochondrial proteins Plasma proteins Predicted membrane proteins
| | | | | Expressed in all |
CYP51A1 | Cytochrome P450, family 51, subfamily A, polypeptide 1 | Enzymes FDA approved drug targets Predicted membrane proteins
| | | | | Expressed in all |
DHODH | Dihydroorotate dehydrogenase (quinone) | Disease related genes Enzymes FDA approved drug targets Mitochondrial proteins Predicted membrane proteins
| | | | | Expressed in all |
EDNRB | Endothelin receptor type B | Disease related genes FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Mixed |
EGFR | Epidermal growth factor receptor | Cancer-related genes Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted membrane proteins Predicted secreted proteins RAS pathway related proteins
| | | | | Tissue enhanced |
ERBB2 | V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2 | Cancer-related genes CD markers Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Expressed in all |
FGFR2 | Fibroblast growth factor receptor 2 | Cancer-related genes CD markers Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted membrane proteins Predicted secreted proteins RAS pathway related proteins
| | | | | Mixed |
FLT4 | Fms-related tyrosine kinase 4 | Cancer-related genes Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted membrane proteins RAS pathway related proteins
| | | | | Mixed |
HDAC6 | Histone deacetylase 6 | Disease related genes Enzymes FDA approved drug targets Predicted membrane proteins
| | | | | Expressed in all |
HRH1 | Histamine receptor H1 | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Mixed |
INSR | Insulin receptor | CD markers Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted membrane proteins RAS pathway related proteins
| | | | | Expressed in all |
ITGA2B | Integrin, alpha 2b (platelet glycoprotein IIb of IIb/IIIa complex, antigen CD41) | Cancer-related genes Candidate cardiovascular disease genes CD markers Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins
| | | | | Tissue enhanced |
ITGB1 | Integrin, beta 1 (fibronectin receptor, beta polypeptide, antigen CD29 includes MDF2, MSK12) | Cancer-related genes CD markers FDA approved drug targets Plasma proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Expressed in all |
KCNC2 | Potassium voltage-gated channel, Shaw-related subfamily, member 2 | FDA approved drug targets Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enriched |
MET | Met proto-oncogene | Cancer-related genes Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted membrane proteins Predicted secreted proteins RAS pathway related proteins
| | | | | Mixed |
MMP15 | Matrix metallopeptidase 15 (membrane-inserted) | Cancer-related genes Enzymes FDA approved drug targets Plasma proteins Predicted membrane proteins
| | | | | Mixed |
MPL | Myeloproliferative leukemia virus oncogene | Cancer-related genes CD markers Disease related genes FDA approved drug targets Predicted membrane proteins
| | | | | Not detected |
PDE3A | Phosphodiesterase 3A, cGMP-inhibited | Enzymes FDA approved drug targets Plasma proteins Predicted membrane proteins
| | | | | Tissue enhanced |
RET | Ret proto-oncogene | Cancer-related genes Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted membrane proteins
| | | | | Tissue enriched |
RRM2 | Ribonucleotide reductase M2 | Enzymes FDA approved drug targets Plasma proteins Predicted membrane proteins
| | | | | Tissue enhanced |
RRM2B | Ribonucleotide reductase M2 B (TP53 inducible) | Disease related genes Enzymes FDA approved drug targets Predicted membrane proteins
| | | | | Expressed in all |
SCNN1D | Sodium channel, non-voltage-gated 1, delta subunit | FDA approved drug targets Predicted membrane proteins
| | | | | Mixed |
SOAT1 | Sterol O-acyltransferase 1 | Enzymes FDA approved drug targets Predicted membrane proteins
| | | | | Tissue enriched |
SV2A | Synaptic vesicle glycoprotein 2A | FDA approved drug targets Predicted membrane proteins
| | | | | Tissue enriched |
SYT2 | Synaptotagmin II | FDA approved drug targets Predicted membrane proteins
| | | | | Tissue enhanced |
TBXAS1 | Thromboxane A synthase 1 (platelet) | Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted membrane proteins
| | | | | Mixed |
TSPO | Translocator protein (18kDa) | Cancer-related genes FDA approved drug targets Mitochondrial proteins Predicted membrane proteins Transporters
| | | | | Expressed in all |